| Paper | Authors | Journal | Year | Type |
|---|
| Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate-to-Severe Endometriosis Pain: A Phase III, Multicentric, Double-Blind, Active-Controlled, Non-Inferiority Study | Bhoir S et al. | BJOG : an international journal of obstetrics and gynaecology | 2026 | Randomized Controlled Trial |
| Single-Dose Bioequivalence Study of Elagolix Tablets [amount hidden] (Test Product) and Elagolix Tablets [amount hidden] (Reference Product) in Healthy Non-Pregnant, Non-Lactating Premenopausal Female Subjects Under Fasting Conditions | Kumar S et al. | Clinical pharmacology in drug development | 2026 | Randomized Controlled Trial |
| Prolonged oral GnRH-antagonist administration before euploid embryo transfer in patients with endometriosis: a prospective randomized pilot non-inferiority trial | Surrey ES et al. | Reproductive biomedicine online | 2025 | Clinical Study |
| Inflammatory Changes after Medical Suppression of Suspected Endometriosis for Implantation Failure: Preliminary Results | Lessey BA et al. | International journal of molecular sciences | 2024 | Randomized Controlled Trial |
| Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial | Miller CE et al. | American journal of obstetrics and gynecology | 2024 | Randomized Controlled Trial |
| Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study | Parke S et al. | BMC women's health | 2024 | Randomized Controlled Trial |
| Bioequivalence of Elagolix/Estradiol/Norethindrone Acetate Fixed-Dose Combination Product: Phase 1 Results in Healthy Pre- and Postmenopausal Women | Chen MJ et al. | Clinical pharmacology in drug development | 2024 | Randomized Controlled Trial |
| Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas: A Randomized Controlled Trial | Brown E et al. | Obstetrics and gynecology | 2023 | Randomized Controlled Trial |
| Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids | Stewart EA et al. | Journal of women's health (2002) | 2022 | Randomized Controlled Trial |
| Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients | Abrao MS et al. | BMC women's health | 2021 | Clinical Trial, Phase III |
| Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis | Pokrzywinski RM et al. | Fertility and sterility | 2021 | Randomized Controlled Trial |
| Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist | Polepally AR et al. | Journal of clinical pharmacology | 2020 | Clinical Trial, Phase I |
| Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain | Abbas Suleiman A et al. | CPT: pharmacometrics & systems pharmacology | 2020 | Clinical Trial, Phase III |
| Clinically Meaningful Reduction in Dyspareunia Is Associated With Significant Improvements in Health-Related Quality of Life Among Women With Moderate to Severe Pain Associated With Endometriosis: A Pooled Analysis of Two Phase III Trials of Elagolix | Agarwal SK et al. | The journal of sexual medicine | 2020 | Randomized Controlled Trial |
| Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas | Simon JA et al. | Obstetrics and gynecology | 2020 | Randomized Controlled Trial |
| Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids | Schlaff WD et al. | The New England journal of medicine | 2020 | Randomized Controlled Trial |
| Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials | Pokrzywinski RM et al. | American journal of obstetrics and gynecology | 2020 | Randomized Controlled Trial |
| Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women | Archer DF et al. | The Journal of clinical endocrinology and metabolism | 2020 | Randomized Controlled Trial |
| Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials | Pokrzywinski RM et al. | Fertility and sterility | 2019 | Randomized Controlled Trial |
| Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis | Surrey ES et al. | Fertility and sterility | 2019 | Randomized Controlled Trial |
| Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA | Wang ST et al. | Journal of comparative effectiveness research | 2019 | Clinical Trial, Phase III |
| Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment | Ng J et al. | Clinical pharmacology in drug development | 2019 | Clinical Trial, Phase I |
| Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial | Carr BR et al. | Obstetrics and gynecology | 2018 | Randomized Controlled Trial |
| Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies | Surrey E et al. | Obstetrics and gynecology | 2018 | Randomized Controlled Trial |
| Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study | Archer DF et al. | Fertility and sterility | 2017 | Randomized Controlled Trial |
| Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist | Taylor HS et al. | The New England journal of medicine | 2017 | Randomized Controlled Trial |
| Dose-Dependent Suppression of Gonadotropins and Ovarian Hormones by Elagolix in Healthy Premenopausal Women | Ng J et al. | The Journal of clinical endocrinology and metabolism | 2017 | Randomized Controlled Trial |
| Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density | Carr B et al. | Reproductive sciences (Thousand Oaks, Calif.) | 2014 | Randomized Controlled Trial |
| Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study | Diamond MP et al. | Reproductive sciences (Thousand Oaks, Calif.) | 2014 | Randomized Controlled Trial |
| Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix | Struthers RS et al. | The Journal of clinical endocrinology and metabolism | 2009 | Randomized Controlled Trial |